The Pharmacist Write Resources Hub

Why Employers Stay with PBMs They Don’t Trust
I Built a Crawler for BCBS Illinois Drug PA Policies. Here’s What I Found—and Why It Extends Beyond Illinois
I Built a Crawler for Cigna’s Drug PA Policies. Here’s What I Found
I Built a Crawler for Medica’s Drug PA Policies. Here’s What I Found—and Why It’s Bigger Than Medica
I Built a Crawler for UnitedHealthcare’s Drug PA Policies. Here’s What I Found
I Built a Crawler for Highmark’s Drug PA Policies. Here’s What I Found
Humira’s Denouement: The Biosimilar “Cliff” That Became a Slope
You Can Appeal Your Denial. You Can’t Appeal the Policy.
The Risk Your Health Plan Can’t See: How Discount Drug Cards Hide True Costs
Class Policy vs. Individual Drug Policy: Cystic Fibrosis Medications as a Case Example
The Reese’s Prescription: Administrative Pathogenesis
When the Claim Clears, but Access Doesn’t
A Small Ambiguity in Drug Coverage Criteria
Watchdoggery, Unencumbered
On Surveillance
On Monopoly
Adversarial Interoperability as an Ethic (and Why Policy Vault Exists)
Wegovy Tablets: What to Know, What Changes, and What Stays the Same
Entrusting Resilience: Cardinal Signs and the Discipline of Not Intervening
On Forgiveness
On Debt
On Automation
When the CEO Calls: Drug Spend Stewardship Under Commercial Pressure
On Dissent
On Regulation
On Scarcity
The Work of Self-Accord
The Originator Ethic: Freshness, Lineage, and Your Voice
Capture, Constraints, and the Art of Self-Legibility
GLP-1 Chaos and the Gymnastics of U.S. Drug Coverage
A Network, Not a Funnel: The Lily-Pad Web as Reader Respect
When Exploration Looks Like Comfort: How Expertise Is Really Built
Long-Chain Contextual Reframing: Restoring Meaning Through Context
The Employer’s Guide to PBMs & Drug Coverage
It’s Agentic: Boogie Woogie Woogie
Beyond the PDF: Why We Need a “Compositional Grammar” for Coverage Rules
The 90% Problem: Why GenAI Alone Can’t Solve Prior Authorization
Policy Vault: from PDFs and Portals to FHIR‑Ready Coverage Rules
GLP‑1 Coverage & Prior Authorization Checklist (Full, Updated 2026 Guide)
Part 9: Bonus — Underwriting Transparent Drug Coverage
Part 8: The Fall of Rebates and the Rise of NodeID — Toward Transparent, Fixed-Gain Drug Access
Sunset Strategy: How Amgen’s Repatha Shows the Future of Late-Stage Asset Pharma Pricing
On Attention
Strensiq: An End‑to‑End FWA Risk Scenario
How Pharmacy Payers Change Policy: A Process Overview
ACC/AHA’s 2025 Guideline Playbook: How to Build Care—and Tools—That Earn Trust
On Exploitation
From Chaos to Counsel: A Framework for Facilitative Promotion
Alternative Careers for Pharmacists: Expand Your Path
Covered Calls: Building Your First Income Stream